Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment
Open accessAbstract
Introduction: We recently uncovered a signaling mechanism by which the endocannabinoid anandamide mediates the action of oxytocin, a neuropeptide that is crucial for social behavior, to control social reward. Oxytocin signaling has been implicated in autism spectrum disorder (ASD), and social reward is a key aspect of social functioning that is thought to be disrupted in ASD. Therefore, as a proof of principle for the core component of ASD—social impairment—we tested an endocannabinoid-enhancing compound on two widely studied mouse models of ASD, the BTBR and fmr1−/− (model of Fragile X Syndrome). Methods: We used the established three-chambered social approach test. We specifically increased the activity of anandamide by administering the compound URB597, a selective inhibitor of fatty acid amide hydrolase (FAAH), the hydrolytic enzyme for anandamide. Results: Remarkably, we found that FAAH blockade completely reversed the social impairment in both mouse models. CB1 receptor blockade prevented the prosocial action of FAAH inhibition in BTBR mice. These results were likely independent of effects on anxiety, as FAAH inhibition did not alter the performance of BTBR mice in the elevated plus maze. Conclusions: The results suggest that increasing anandamide activity at CB1 receptors improves ASD-related social impairment and identify FAAH as a novel therapeutic target for ASD.
AI snapshot
Written from the paper’s full text.
TL;DR
In two mouse models of autism-related social impairment, pharmacological inhibition of FAAH with URB597 increased anandamide signaling and corrected social approach deficits; the effect in BTBR mice was blocked by CB1 antagonism and was not explained by reduced anxiety. These findings identify FAAH as a candidate therapeutic target for ASD-related social impairment.
Key findings
- URB597 (0.3 or 1 mg/kg i.p., 3 h before testing) significantly increased social chamber time and sniffing in BTBR mice to levels comparable to C57Bl6J controls; concomitant AM251 (2 mg/kg i.p.) prevented this prosocial effect (n=12–16).
- In fmr1−/− mice, URB597 (0.3 mg/kg i.p.) increased social chamber time and sniffing to control levels, while no effect was seen in wild-type fmr1+/+ (FVB/NJ) mice; the baseline fmr1−/− social deficit was not statistically significant in this study (n=12–14 per group).
- URB597 inhibited FAAH and substantially increased forebrain anandamide in BTBR mice without affecting 2-AG. In the elevated plus maze, URB597 (1 mg/kg i.p.) did not alter open-arm time or entries in BTBR mice (n=10 per group), suggesting the prosocial effect was not due to general anxiolysis.
- In socially normal C57Bl6J mice, neither AM251 (2 mg/kg i.p.) nor URB597 (1 mg/kg i.p.) altered social chamber time or sniffing.
Methods
- Preclinical proof-of-principle study using male mice (8–10 weeks) bred at UC Irvine, group-housed and naive for each behavioral experiment. Models included BTBR, fmr1−/− (FVB/NJ), C57Bl6J, and wild-type fmr1+/+.
- Behavioral testing used the three-chamber social approach test (10-min test; choice between novel object and a sex-, age-, and weight-matched 129/SvImJ mouse; 5 lux lighting; automated chamber-time scoring and blinded sniffing scoring) and the elevated plus maze. Biochemical assays included a FAAH enzymatic activity assay and LC/MS lipid quantification.
- URB597 and AM251 were administered i.p. 3 h before testing. Statistical analysis used two-tailed Student’s t-test and one-way or two-way ANOVA with Tukey’s post hoc test; significance was p<0.05 (GraphPad Prism).
Limitations
- Stated in the paper: interpretation of BTBR data is limited by possible polygenetic contributions to this inbred strain’s phenotype; fmr1−/− mice were not tested in the elevated plus maze because they display an innate open-arm preference that could confound interpretation; the social approach test may have a ceiling effect and is typically a screening tool rather than a continuous measure of sociability.
- Evident from the text: only male mice were studied, drug treatment was acute, and no chronic dosing, safety, or human data are reported.
- Evident from the text: the fmr1−/− baseline social deficit was not statistically significant in this study, and the proposed oxytocin–anandamide reward mechanism was not directly tested in these ASD models.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 44 cited sources checked · 0 supported · 0 flagged
- Findingown data
URB597 inhibited FAAH in the forebrain of BTBR mice.
“Using an enzymatic activity assay and LC/MS, we confirmed that URB597 inhibited FAAH and substantially increased the levels of anandamide in the forebrain of BTBR mice (Fig. 2a, b), without affecting levels of the other endocannabinoid 2-arachidonoyl-sn-glycerol (2-AG) (Fig. 2c).”
Quote in the paperSubstantial claim - Findingown data
Administration of URB597 (0.3 or 1 mg/kg i.p., 3 h before testing) significantly increased the time BTBR mice spent in the social chamber and sniffing, to levels comparable to those displayed by control, socially normal C57Bl6J mice.
“However, administration of URB597 (0.3 or 1 mg kg−1, i.p., 3 h before testing) significantly increased the time BTBR mice spent in the social chamber and sniffing, to levels that were comparable to those displayed by control, socially normal C57Bl6J mice (Fig. 1c, d).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [25] source
Not checked in the free run.
- Findingown data
URB597 did not affect levels of 2-arachidonoyl-sn-glycerol (2-AG) in the forebrain of BTBR mice.
“Using an enzymatic activity assay and LC/MS, we confirmed that URB597 inhibited FAAH and substantially increased the levels of anandamide in the forebrain of BTBR mice (Fig. 2a, b), without affecting levels of the other endocannabinoid 2-arachidonoyl-sn-glycerol (2-AG) (Fig. 2c).”
Quote in the paperSubstantial claim - Findingown data
Concomitant administration of AM251 (2 mg/kg i.p.) prevented the effect of FAAH inhibition on social approach in BTBR mice.
“The effect of FAAH inhibition on social approach depended on CB1 receptors and, thus, presumably on anandamide accumulation, because it was prevented by concomitant administration of AM251 (2 mg kg−1, i.p.) (Fig. 1c, d).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [29] source
Not checked in the free run.
- Findingcitation
BTBR mice show no social preference in the three-chambered social approach test.
“In contrast to C57Bl6J mice, BTBR mice show no social preference in the test (Fig. 1c, d).20,21”
Quote in the paperSubstantial claim0 of 2 sources checked
- Findingown data
URB597 substantially increased the levels of anandamide in the forebrain of BTBR mice.
“Using an enzymatic activity assay and LC/MS, we confirmed that URB597 inhibited FAAH and substantially increased the levels of anandamide in the forebrain of BTBR mice (Fig. 2a, b), without affecting levels of the other endocannabinoid 2-arachidonoyl-sn-glycerol (2-AG) (Fig. 2c).”
Quote in the paperSubstantial claim - Findingown data
In our hands, fmr1−/− mice did not show a statistically significant deficit in social approach.
“Fmr1−/− mutant mice bred on an FVB/NJ background have been reported to exhibit a deficit in social approach.22 In our hands, however, this deficit was not statistically significant (Fig. 4a, b).”
Quote in the paperNot a substantial claim - Findingown data
Acute administration of URB597 (0.3 mg/kg i.p.) did not alter the time spent in the social chamber or sniffing in wild-type fmr1+/+ (FVB/NJ) mice.
“Nevertheless, we found that acute administration of URB597 (0.3 mg kg−1, i.p.), which did not alter the time spent in the social chamber or sniffing in wild-type fmr1+/+ (FVB/NJ) mice (Fig. 4a–c), increased the time spent by fmr1−/− mice in the social chamber and the time spent sniffing to levels to those displayed by control mice (Fig. 4a–c).”
Quote in the paperSubstantial claim - Premisecitation
A core feature across autism spectrum disorder (ASD) is impairment in social functioning.
“A core feature across autism spectrum disorder (ASD) is impairment in social functioning.1,2”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
In isolated male mice, specifically stimulating oxytocin neurons in the paraventricular nucleus of the hypothalamus drives anandamide mobilization in the NAc.
“Conversely, in isolated male mice, specifically stimulating oxytocin neurons in the paraventricular nucleus of the hypothalamus drives anandamide mobilization in the NAc.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
- Premisecitation
Anandamide enhancement offsets the effects of oxytocin receptor blockade on social reward and NAc activity.
“Anandamide enhancement offsets the effects of oxytocin receptor blockade on social reward and NAc activity.15”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
- Premisecitation
Oxytocin drives anandamide-mediated signaling at CB1 receptors to control the rewarding properties of social interactions.
“we identified a signaling mechanism by which oxytocin drives anandamide-mediated signaling at CB1 receptors to control the rewarding properties of social interactions.15”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
- Premiseown data
Genetic removal of FAAH in mice increases direct social interactions.
“we found that genetic removal of FAAH in mice increases direct social interactions,13”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [13] source
Not checked in the free run.
- Premisecitation
Social contact among male mice stimulates the mobilization of anandamide in the nucleus accumbens in an oxytocin-dependent manner.
“Social contact among male mice stimulates the mobilization of anandamide in the nucleus accumbens (NAc), a key brain region for reward signaling, in an oxytocin-dependent manner.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
- Interpretationown data
The effect of FAAH inhibition on social approach in BTBR mice depends on CB1 receptors.
“The effect of FAAH inhibition on social approach depended on CB1 receptors and, thus, presumably on anandamide accumulation, because it was prevented by concomitant administration of AM251 (2 mg kg−1, i.p.) (Fig. 1c, d).”
Quote in the paperSubstantial claim - Premisecitation
BTBR mice have abnormal oxytocin expression in the hypothalamus.
“Consistent with this idea, BTBR mice were found to have abnormal oxytocin expression in the hypothalamus.45”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [45] source
Not checked in the free run.
- Premisecitation
Negative allosteric GABA modulation in C57Bl6J mice recapitulates social impairment.
“Enhancing GABAergic activity in BTBR mice ameliorates their social impairment, and negative allosteric GABA modulation in C57Bl6J mice recapitulates social impairment.48”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [48] source
Not checked in the free run.
- Interpretationown data
FAAH is a novel therapeutic target for ASD.
“The results suggest that increasing anandamide activity at CB1 receptors improves ASD-related social impairment and identify FAAH as a novel therapeutic target for ASD.”
- Also stated in: § Discussion · hedged
“Together, the results put forth FAAH as a novel therapeutic target for ASD-related social impairment.”
Quote in the paperSubstantial claim - Also stated in: § Discussion · hedged
- Premisecitation
Enhancing GABAergic activity in BTBR mice ameliorates their social impairment.
“Enhancing GABAergic activity in BTBR mice ameliorates their social impairment, and negative allosteric GABA modulation in C57Bl6J mice recapitulates social impairment.48”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [48] source
Not checked in the free run.
- Interpretationown data
Increasing anandamide activity at CB1 receptors improves ASD-related social impairment.
“The results suggest that increasing anandamide activity at CB1 receptors improves ASD-related social impairment and identify FAAH as a novel therapeutic target for ASD.”
Quote in the paperSubstantial claim - Interpretationown data
The modulation of stress reactivity and social behavior can be dissociable.
“While this phenotype does not exclude more nuanced forms of social anxiety, it does support the idea that the modulation of stress reactivity and social behavior can be dissociable.”
Quote in the paperSubstantial claim - Premisecitation
BTBR mice are deficient in conditioned place preference to social interactions.
“BTBR mice were also reported to be deficient in conditioned place preference to social interactions.46”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [46] source
Not checked in the free run.
- Interpretationown data
The prosocial action of FAAH blockade is selective for social impairment in certain contexts.
“Nevertheless, our set of results suggests that the prosocial action of FAAH blockade is selective for social impairment in certain contexts, which may be therapeutically advantageous for the spectral nature of ASD.”
Quote in the paperSubstantial claim - Interpretationown data
The prosocial effect of FAAH inhibition in BTBR mice is independent of reduced anxiety.
“suggesting that the prosocial effect of this compound cannot be attributed to reduced anxiety.”
- Also stated in: § Discussion · plain
“Furthermore, we show that the prosocial action of FAAH inhibition is independent of reducing anxiety in BTBR mice.”
Quote in the paperSubstantial claim - Also stated in: § Discussion · plain
- Premisecitation
Chronic isolation increases 2-AG in the prefrontal cortex without affecting anandamide.
“For instance, we found that chronic isolation increases 2-AG in the prefrontal cortex, without affecting anandamide, and increases both 2-AG and anandamide in the piriform cortex.35”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [35] source
Not checked in the free run.
- May combine two claims. 11
- Classified as probably not a substantial claim. 25
May combine two claims.
Findingown dataURB597 (1 mg/kg i.p.) administered to BTBR mice did not alter the time spent in the open arms or the number of open-arm entries in the elevated plus maze under dim lighting conditions (5 lux).
“We found that URB597 (1 mg kg−1, i.p.) administered to BTBR mice did not alter the time spent in the open arms, or the number of open-arm entries (Fig. 3a–c), suggesting that the prosocial effect of this compound cannot be attributed to reduced anxiety.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataNeither AM251 (2 mg/kg i.p.) nor URB597 (1 mg/kg i.p.) altered the time spent in the social chamber or the time spent sniffing the target mouse in socially normal C57Bl6J mice.
“We first evaluated maximally effective doses of AM251 (2 mg kg−1, i.p.)29 or URB597 (1 mg kg−1, i.p.)25 in socially normal C57Bl6J mice and found that neither drug altered the two outcome measures of the test, namely the time spent in the social chamber and the time spent sniffing the target mouse (Fig. 1a, b).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
Findingown dataAcute administration of URB597 (0.3 mg/kg i.p.) increased the time spent by fmr1−/− mice in the social chamber and the time spent sniffing to levels displayed by control mice.
“Nevertheless, we found that acute administration of URB597 (0.3 mg kg−1, i.p.), which did not alter the time spent in the social chamber or sniffing in wild-type fmr1+/+ (FVB/NJ) mice (Fig. 4a–c), increased the time spent by fmr1−/− mice in the social chamber and the time spent sniffing to levels to those displayed by control mice (Fig. 4a–c).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe social motivation theory posits that the psychopathology of ASD is rooted in a decreased desire to be social.
“One theory—the social motivation theory—posits that the psychopathology of ASD is rooted in a decreased desire to be social.3,4”
Quote in the paperNot a substantial claim0 of 2 sources checkedClassified as probably not a substantial claim. May combine two claims.
PremisecitationPeople with ASD restrict themselves to repetitive behaviors and show deficits in social reciprocity and communication.
“People with ASD restrict themselves to repetitive behaviors and show deficits in social reciprocity and communication.1”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] source
Not checked in the free run.
May combine two claims.
PremisecitationConsequent activation of CB1 receptors is necessary and sufficient to regulate social reward.
“Consequent activation of CB1 receptors is necessary and sufficient to regulate social reward.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationOxytocin is crucial in many aspects of social behavior, including affiliation and reward.
“This neuropeptide is crucial in many aspects of social behavior, including affiliation6 and reward.7”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationAcutely intoxicated marijuana users enjoy interacting more and feel more connected and empathetic.
“Acutely intoxicated marijuana users enjoy interacting more and feel more connected and empathetic.16,17”
Quote in the paperNot a substantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
PremisecitationFatty acid amide hydrolase (FAAH) catalyzes the intracellular hydrolysis of the endocannabinoid anandamide.
“Fatty acid amide hydrolase (FAAH) catalyzes the intracellular hydrolysis of the endocannabinoid anandamide.”
Quote in the paperSubstantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
PremisecitationPharmacological FAAH inhibition promotes social play in juvenile rats.
“Trezza et al. noted that pharmacological FAAH inhibition promotes social play in juvenile rats.14”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [14] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationA polymorphism in the CB1 cannabinoid receptor gene modulates social gaze.
“Chakrabarti and Baron-Cohen reported that a polymorphism in the CB1 cannabinoid receptor gene modulates social gaze.18”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [18] source
Not checked in the free run.
Classified as probably not a substantial claim.
PremisecitationFAAH inhibition results in anxiolytic-like effects only under high-light conditions.
“This result is in line with previous reports showing that FAAH inhibition results in anxiolytic-like effects only under “high-light” conditions.42”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [42] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationCB1 receptors are present on presynaptic terminals of both glutamatergic projection neurons and GABAergic interneurons.
“This view is consistent with the presence of CB1 receptors on presynaptic terminals of both glutamatergic projection neurons and GABAergic interneurons.11”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [11] source
Not checked in the free run.
May combine two claims.
Interpretationown dataFAAH inhibition is an appropriate strategy to elevate levels of anandamide, and thus anandamide signaling, in BTBR mice.
“We confirm that FAAH inhibition is an appropriate strategy to elevate levels of anandamide, and thus, anandamide signaling, in BTBR mice.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataThe prosocial action of increased anandamide activity through FAAH inhibition is generalizable across at least two distinct models of ASD-related social impairment, without affecting socially normal animals.
“These results suggest that the prosocial action of increased anandamide activity (through FAAH inhibition) is generalizable across at least two distinct models of ASD-related social impairment, without affecting socially normal animals.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationCB1 overexpression in the medial prefrontal cortex alters social interactions without overtly changing the anxiety-related phenotype.
“In line with this notion, CB1 overexpression in the medial prefrontal cortex alters social interactions without overtly changing the anxiety-related phenotype.43”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [43] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationCB1 agonists impair social play in rats.
“CB1 agonists impair social play in rats.39”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [39] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationDeletion of FMRP impairs the formation of a key signaling complex that links mGluR5 and DGL-α.
“In a related example, we found that deletion of FMRP, the mRNA-trafficking protein missing in Fragile X Syndrome, impairs the formation of a key signaling complex that links metabotropic glutamate receptor-5 (mGluR5) and the 2-AG-synthesizing enzyme diacylglycerol lipase-α (DGL-α).28”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [28] Jung K-M, 2012, Nat Commun
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenAll procedures met the National Institute of Health guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee at the University of California, Irvine.
“All procedures met the National Institute of Health guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee at the University of California, Irvine.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
InterpretationcitationThe bidirectional modulation of social behavior likely depends on the dose and the identity of the affected circuits.
“Thus, the bidirectional modulation of social behavior likely depends on the dose and the identity of the affected circuits.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationGenetic removal of CB1 receptors alters social interactions in mice in a context-dependent manner.
“Genetic removal of CB1 receptors alters social interactions in mice in a context-dependent manner,32 which may be related to social anxiety and/or cognition.37,38”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [32] source
Not checked in the free run.
Classified as probably not a substantial claim.
Study design and conductnone givenSniffing time was scored by trained assistants who were unaware of treatment conditions.
“Sniffing time was scored by trained assistants who were unaware of treatment conditions.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationHuman studies have found that marijuana may enhance sociability.
“In addition, human studies have found that marijuana may enhance sociability16,17 and a polymorphism in the CB1 cannabinoid receptor gene modulates social gaze.18”
Quote in the paperNot a substantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationChronic isolation increases both 2-AG and anandamide in the piriform cortex.
“For instance, we found that chronic isolation increases 2-AG in the prefrontal cortex, without affecting anandamide, and increases both 2-AG and anandamide in the piriform cortex.35”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [35] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenSubjects with outlying inactivity were excluded.
“Excluded were subjects with outlying inactivity.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenObject/mouse side placement was counterbalanced between trials.
“Object/mouse side placement was counterbalanced between trials.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationMutations in neuroligins impair tonic endocannabinoid signaling.
“For example, mutations in neuroligins, a family of ASD-linked synaptic adhesion proteins, impair tonic endocannabinoid signaling.34”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [34] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationDevelopmental treatment with valproic acid reduces hippocampal mRNA levels of the 2-AG-hydrolyzing enzyme monoacylglycerol lipase.
“Furthermore, developmental treatment with valproic acid reduces cerebellar mRNA levels of DGL-α and reduces hippocampal mRNA levels of the 2-AG-hydrolyzing enzyme monoacylglycerol lipase.36”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [36] Kerr DM, 2013, Behav Brain Res
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationDevelopmental treatment with valproic acid reduces cerebellar mRNA levels of DGL-α.
“Furthermore, developmental treatment with valproic acid reduces cerebellar mRNA levels of DGL-α and reduces hippocampal mRNA levels of the 2-AG-hydrolyzing enzyme monoacylglycerol lipase.36”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [36] Kerr DM, 2013, Behav Brain Res
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenThe apparatus was thoroughly cleaned with SCOE 10X odor eliminator between trials to preclude olfactory confounders.
“The apparatus was thoroughly cleaned with SCOE 10X odor eliminator (BioFOG) between trials to preclude olfactory confounders.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenNaive mice were used for each behavioral experiment.
“Naive mice were used for each behavioral experiment.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductcitationPreviously established methods were followed for the three-chambered social approach task.
“Previously established methods were followed.21”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [21] Silverman JL, 2012, Sci Transl Med source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductcitationThe elevated plus maze procedure was based on previously published methods.
“The procedure was based on previously published methods.28”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [28] Jung K-M, 2012, Nat Commun
Not checked in the free run.
The paper relies on this without support.
The underlying basis for social impairment in ASD is unknown, and no pharmacological treatment is available.
“The underlying basis for social impairment in ASD is unknown, and no pharmacological treatment is available.”
The paper relies on this without support.
Social reward is a key aspect of social functioning that is disrupted in ASD.
“social reward is a key aspect of social functioning that is thought to be disrupted in ASD.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Animal models of both FXS and ASD have shown benefits when treated with CBD.
“Animal models of both FXS and ASD have shown benefits when treated with CBD [121, 122].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [122]
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369 · see citing works
Neocortical excitation/inhibition balance in information processing and social dysfunction
Yizhar, O., Fenno, L. E., Prigge, M., Schneider, F., Davidson, T. J., O’Shea, D. J., Sohal, V. S., Goshen, I., Finkelstein, J., Paz, J. T., et al. (2011) · Nature · doi:10.1038/nature10360 · Cited by 2,454 · see citing works
The social motivation theory of autism
Chevallier, C., Kohls, G., Troiani, V., Brodkin, E. S., & Schultz, R. T. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2012.02.007 · Cited by 2,072 · see citing works
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · see citing works
Self-citationCognitive neuroscience of human social behaviour
Adolphs, R. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1056 · Cited by 1,657 · see citing works
Behavioural phenotyping assays for mouse models of autism
Silverman, J. L., Yang, M., Lord, C., & Crawley, J. N. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2851 · Cited by 1,462 · see citing works
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · see citing works
Self-citationSocial reward requires coordinated activity of nucleus accumbens oxytocin and serotonin
Dölen, G., Darvishzadeh, A., Huang, K. W., & Malenka, R. C. (2013) · Nature · doi:10.1038/nature12518 · Cited by 1,161 · see citing works
Insel, T. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.03.005 · Cited by 1,044 · see citing works
Autism‐like behavioral phenotypes in BTBR T+tf/J mice
McFarlane, H. G., Kusek, G. K., Yang, M., Phoenix, J. L., Bolivar, V. J., & Crawley, J. N. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00330.x · Cited by 812 · see citing works
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 663 · see citing works
Lord, C., Cook, E. H., Leventhal, B. L., & Amaral, D. G. (2000) · Neuron · doi:10.1016/s0896-6273(00)00115-x · Cited by 555 · see citing works
Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004) · Endocrinology · doi:10.1210/en.2004-0638 · Cited by 475 · see citing works
The emerging functions of endocannabinoid signaling during CNS development
Harkany, T., Guzmán, M., Galve‐Roperh, I., Berghuis, P., Devi, L. A., & Mackie, K. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.12.004 · Cited by 432 · see citing works
Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427 · see citing works
Self-citationKaufmann, W. E., Cortell, R., Kau, A. S. M., Bukelis, I., Tierney, E., Gray, R. M., Cox, C., Capone, G. T., & Stanard, P. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30229 · Cited by 397 · see citing works
Exogenous and evoked oxytocin restores social behavior in the <i>Cntnap2</i> mouse model of autism
Peñagarikano, O., Lázaro, M. T., Lu, X.-H., Gordon, A., Dong, H., Lam, H. A., Peles, E., Maidment, N. T., Murphy, N. P., Yang, X. W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010257 · Cited by 378 · see citing works
Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.162 · Cited by 344 · see citing works
Autism-Associated Neuroligin-3 Mutations Commonly Disrupt Tonic Endocannabinoid Signaling
Földy, C., Malenka, R. C., & Südhof, T. C. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.036 · Cited by 287 · see citing works
Haller, J., Varga, B., Ledent, C., Barna, I., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03293.x · Cited by 284 · see citing works
Fraser, G. A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00071.x · Cited by 283 · cited 2× · see citing works
“is particularly important in light of the known roles of endocannabinoids in stress modulation.(19,30,40,41) In our case, we found that the prosocial action of ananda-”
BackgroundMoreira, F. A., Kaiser, N., Monory, K., & Lutz, B. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.005 · Cited by 282 · see citing works
Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome
Jung, K., Sepers, M. D., Henstridge, C. M., Lassalle, O., Neuhofer, D. N., Martin, H. G. S., Ginger, M. R., Frick, A., DiPatrizio, N. V., Mackie, K., et al. (2012) · Nature Communications · doi:10.1038/ncomms2045 · Cited by 282 · see citing works
Self-citationMarijuana Intoxication : Common Experiences
TART, C. T. (1970) · Nature · doi:10.1038/226701a0 · Cited by 252 · see citing works
Silverman, J. L., Smith, D. G., Rizzo, S. J. S., Karras, M. N., Turner, S. M., Tolu, S. S., Bryce, D. K., Smith, D. L., Fonseca, K., Ring, R. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003501 · Cited by 251 · see citing works
Social approach in genetically engineered mouse lines relevant to autism
Moy, S. S., Nadler, J. J., Young, N. B., Nonneman, R. J., Grossman, A. W., Murphy, D. L., D’Ercole, A. J., Crawley, J. N., Magnuson, T. R., & Lauder, J. M. (2009) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2008.00452.x · Cited by 246 · see citing works
Han, S., Tai, C., Jones, C. J., Scheuer, T., & Catterall, W. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.016 · Cited by 231 · see citing works
Hussman, J. P., Chung, R.-H., Griswold, A. J., Jaworski, J. M., Salyakina, D., Ma, D., Konidari, I., Whitehead, P. L., Vance, J. M., Martin, E. R., et al. (2011) · Molecular Autism · doi:10.1186/2040-2392-2-1 · Cited by 231 · see citing works
The oxytocin system in drug discovery for autism: Animal models and novel therapeutic strategies
Modi, M. E., & Young, L. J. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.010 · Cited by 218 · see citing works
Endocannabinoid signaling mediates oxytocin-driven social reward
Wei, D., Lee, D., Cox, C. D., Karsten, C. A., Peñagarikano, O., Geschwind, D. H., Gall, C. M., & Piomelli, D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509795112 · Cited by 218 · see citing works
Self-citationToward a Neural Basis for Social Behavior
Stanley, D. A., & Adolphs, R. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.038 · Cited by 213 · see citing works
Endocannabinoids in Amygdala and Nucleus Accumbens Mediate Social Play Reward in Adolescent Rats
Trezza, V., Damsteegt, R., Manduca, A., Petrosino, S., Van Kerkhof, L. W. M., Pasterkamp, R. J., Zhou, Y., Campolongo, P., Cuomo, V., Di Marzo, V., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0114-12.2012 · Cited by 190 · see citing works
Alterations in the endocannabinoid system in the rat valproic acid model of autism
Kerr, D. M., Downey, L., Conboy, M., Finn, D. P., & Roche, M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.04.043 · Cited by 183 · see citing works
Social behavior deficits in the Fmr1 mutant mouse
Mineur, Y. S., Huynh, L. X., & Crusio, W. E. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.11.004 · Cited by 177 · see citing works
Inheritable Effect of Unpredictable Maternal Separation on Behavioral Responses in Mice
Weiss, I. C., Franklin, T. B., Vizi, S., & Mansuy, I. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00003 · Cited by 169 · see citing works
Bidirectional cannabinoid modulation of social behavior in adolescent rats
Trezza, V., & Vanderschuren, L. J. M. J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1025-3 · Cited by 159 · see citing works
Low stress reactivity and neuroendocrine factors in the BTBR T+tf/J mouse model of autism
Silverman, J. L., Yang, M., Turner, S. M., Katz, A. M., Bell, D. B., Koenig, J. I., & Crawley, J. N. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.09.059 · Cited by 146 · see citing works
More surprises lying ahead. The endocannabinoids keep us guessing
Piomelli, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.026 · Cited by 128 · see citing works
Self-citationLipidomic analysis of endocannabinoid metabolism in biological samples
Astarita, G., & Piomelli, D. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.01.008 · Cited by 107 · see citing works
Self-citationCB1 receptor signaling regulates social anxiety and memory
Litvin, Y., Phan, A., Hill, M. N., Pfaff, D. W., & McEwen, B. S. (2013) · Genes Brain & Behavior · doi:10.1111/gbb.12045 · Cited by 93 · see citing works
Sciolino, N. R., Bortolato, M., Eisenstein, S. A., Fu, J., Oveisi, F., Hohmann, A. G., & Piomelli, D. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.007 · Cited by 89 · see citing works
Self-citationClapper, J. R., Vacondio, F., King, A. R., Duranti, A., Tontini, A., Silva, C., Sanchini, S., Tarzia, G., Mor, M., & Piomelli, D. (2009) · ChemMedChem · doi:10.1002/cmdc.200900210 · Cited by 74 · see citing works
Self-citationCassano, T., Gaetani, S., Macheda, T., Laconca, L., Romano, A., Morgese, M. G., Cimmino, C. S., Chiarotti, F., Bambico, F. R., Gobbi, G., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2051-0 · Cited by 72 · see citing works
Self-citationTerzian, A. L. B., Micale, V., & Wotjak, C. T. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12561 · Cited by 69 · see citing works
Pearson, B. L., Bettis, J. K., Meyza, K. Z., Yamamoto, L. Y., Blanchard, D. C., & Blanchard, R. J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.04.040 · Cited by 57 · see citing works
McMahon, L. R., & Koek, W. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.04.054 · Cited by 57 · see citing works
Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces
Chakrabarti, B., & Baron-Cohen, S. (2011) · Molecular Autism · doi:10.1186/2040-2392-2-10 · Cited by 57 · see citing works
Klugmann, M., Goepfrich, A., Friemel, C. M., & Schneider, M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00037 · Cited by 49 · see citing works
Marijuana and hostility in a small-group setting
(1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.9.1029 · Cited by 48 · see citing works
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7 · see citing works
Self-citation
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Jung K-M, 2012, Nat Commun, 3, 108
- Kerr DM, 2013, Behav Brain Res, 30, 680
Cited by
Sorted by citations
Uhl, G. R., Koob, G. F., & Cable, J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13989 · Cited by 259 · see citing works
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01183-1 · Cited by 233 · see citing works
Lower circulating endocannabinoid levels in children with autism spectrum disorder
Aran, A. A., Eylon, M., Harel, M., Polianski, L., Nemirovski, A., Tepper, S., Schnapp, A., Cassuto, H., Wattad, N., & Tam, J. (2019) · Molecular Autism · doi:10.1186/s13229-019-0256-6 · Cited by 162 · see citing works
Plasma anandamide concentrations are lower in children with autism spectrum disorder
Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A., Garner, J. P., Hardan, A. Y., & Parker, K. J. (2018) · Molecular Autism · doi:10.1186/s13229-018-0203-y · Cited by 157 · see citing works
Servadio, M., Melancia, F., Manduca, A., di Masi, A., Schiavi, S., Cartocci, V., Pallottini, V., Campolongo, P., Ascenzi, P., & Trezza, V. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.182 · Cited by 139 · see citing works
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models
Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091916 · Cited by 127 · see citing works
An endocannabinoid-regulated basolateral amygdala–nucleus accumbens circuit modulates sociability
Folkes, O. M., Báldi, R., Kondev, V., Marcus, D. J., Hartley, N. D., Turner, B. D., Ayers, J. K., Baechle, J. J., Misra, M. P., Altemus, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131752 · Cited by 119 · see citing works
Endocannabinoid Signaling in the Control of Social Behavior
Don, W., Allsop, S. A., Tye, K. M., & Piomelli, D. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.005 · Cited by 111 · see citing works
Self-citationHeussler, H., Cohen, J., Silove, N., Tich, N., Bonn-Miller, M. O., Du, W., O’Neill, C., & Sebree, T. (2019) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-019-9277-x · Cited by 106 · see citing works
Zamberletti, E., Gabaglio, M., Woolley-Roberts, M., Bingham, S., Rubino, T., & Parolaro, D. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00367 · Cited by 95 · see citing works
Marzo, V. D. (2020) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2020.22.3/vdimarzo · Cited by 91 · see citing works
Doenni, V. M., Gray, J. M., Song, C. M., Patel, S., Hill, M. N., & Pittman, Q. J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.07.152 · Cited by 80 · see citing works
Biosynthesis and synthetic biology of psychoactive natural products
Jamieson, C. S., Misa, J., Tang, Y., & Billingsley, J. M. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00065a · Cited by 71 · see citing works
Endocannabinoid signaling in social functioning: an RDoC perspective
Karhson, D. S., Hardan, A. Y., & Parker, K. J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.169 · Cited by 62 · see citing works
Manduca, A., Bara, A., Larrieu, T., Lassalle, O., Joffre, C., Layé, S., & Manzoni, O. J. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3516-16.2017 · Cited by 63 · see citing works
Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder
Zou, M., Liu, Y., Xie, S. H., Wang, L., Li, D., Li, L., Wang, F., Zhang, Y., Xia, W. T., Sun, C., et al. (2021) · Open Biology · doi:10.1098/rsob.200306 · Cited by 58 · see citing works
Self-citationZamberletti, E., Gabaglio, M., Piscitelli, F., Brodie, J., Woolley-Roberts, M., Barbiero, I., Tramarin, M., Binelli, G., Landsberger, N., Kilstrup‐Nielsen, C., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119844184 · Cited by 58 · see citing works
FMR1 and Autism, an Intriguing Connection Revisited
Fyke, W., & Velinov, M. T. (2021) · Genes · doi:10.3390/genes12081218 · Cited by 59 · see citing works
Tartaglia, N. R., Bonn‐Miller, M. O., & Hagerman, R. J. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0053 · Cited by 57 · see citing works
Kuo, H., & Liu, F. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00422 · Cited by 46 · see citing works
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi, J. F. C., Ferreira, F. R., Silva-Amaral, D., Lima, D. D. A., Hallak, J. E. C., Zuardi, A. W., Bel, E. A. D., Guimarães, F. S., Costa, K. C. M., Campos, A. C., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06196-4 · Cited by 52 · see citing works
Current state of evidence of cannabis utilization for treatment of autism spectrum disorders
Agarwal, R., Burke, S. L., & Maddux, M. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2259-4 · Cited by 46 · see citing works
Wu, H.-F., Lu, T.-Y., Chu, M.-C., Chen, P. S., Lee, C. J., & Lin, H. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107736 · Cited by 45 · see citing works
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition
Papa, A., Pasquini, S., Contri, C., Gemma, S., Campiani, G., Butini, S., Varani, K., & Vincenzi, F. (2022) · Cells · doi:10.3390/cells11030471 · Cited by 45 · see citing works
Mesleh, A. G., Abdulla, S. A., & El‐Agnaf, O. M. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11010041 · Cited by 41 · see citing works
Hill, M. N., Haney, M., Hillard, C. J., Karhson, D. S., & Vecchiarelli, H. A. (2023) · Psychological Medicine · doi:10.1017/s0033291723002465 · Cited by 39 · see citing works
Cannabidiol and Neurodevelopmental Disorders in Children
Cheung, K. A. K., Mitchell, M. D., & Heussler, H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.643442 · Cited by 39 · see citing works
Uso da Cannabis medicinal e autismo
Lima, M. C. M., Valênça, M. M., Machado, C. E., Pereira, M. E. D. M., & Brant, P. K. (2020) · Jornal Memorial da Medicina · doi:10.37085/jmmv2.n1.2020.pp.5-14 · Cited by 37 · see citing works
Scheyer, A. F., Yasmin, F., Naskar, S., & Patel, S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01438-7 · Cited by 36 · see citing works
Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story
Carbone, E., Manduca, A., Cacchione, C., Vicari, S., & Trezza, V. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.009 · Cited by 37 · see citing works
The neurochemistry of social reward during development: What have we learned from rodent models?
Manduca, A., Carbone, E., Schiavi, S., Cacchione, C., Buzzelli, V., Campolongo, P., & Trezza, V. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15321 · Cited by 34 · see citing works
Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder
Zamberletti, E., Rubino, T., & Parolaro, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107878 · Cited by 35 · see citing works
A systematic review of cannabidiol trials in neurodevelopmental disorders
Parrella, N.-F., Hill, A. T., Enticott, P. G., Barhoun, P., Bower, I. S., & Ford, T. C. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173607 · Cited by 34 · see citing works
In the face of stress: Interpreting individual differences in stress-induced facial expressions
Mayo, L. M., & Heilig, M. A. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100166 · Cited by 33 · see citing works
Ponton, J. A., Smyth, K. A., Soumbasis, E., Llanos, S. A., Lewis, M. H., Meerholz, W. A., & Tanguay, R. L. (2020) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02478-7 · Cited by 33 · see citing works
Role of the endocannabinoid system in neurological disorders
Zou, M., Li, D., Li, L., Wu, L., & Sun, C. (2019) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2019.03.002 · Cited by 28 · see citing works
Self-citationMouse models of fragile X-related disorders
Willemsen, R., & Kooy, R. F. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049485 · Cited by 27 · see citing works
Annamneedi, A., Gora, C., Dudas, A., Leray, X., Bozon, V., Crépieux, P., & Pellissier, L. P. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16216 · Cited by 29 · see citing works
Loss, C. M., Teodoro, L., Rodrigues, G. D., Moreira, L. R., Peres, F. F., Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., & Abílio, V. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.635763 · Cited by 27 · see citing works
Rice, L. J., Cannon, L., Dadlani, N., Cheung, M. M. Y., Einfeld, S., Efron, D., Dossetor, D. R., & Elliott, E. J. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02169-w · Cited by 27 · see citing works
Schiavi, S., Manduca, A., Carbone, E., Buzzelli, V., Rava, A., Feo, A., Ascone, F., Morena, M., Campolongo, P., Hill, M. N., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01454-7 · Cited by 26 · see citing works
Holdman, R., Vigil, D., Robinson, K. J., Shah, P., & Contreras, A. E. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0154 · Cited by 31 · see citing works
Pietropaolo, S., & Marsicano, G. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.031 · Cited by 23 · see citing works
Neuhofer, D. N., Lassalle, O., & Manzoni, O. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00398 · Cited by 23 · see citing works
The role of the endocannabinoid system in autism spectrum disorders: Evidence from mouse studies
Pietropaolo, S., Bellocchio, L., Bouzón‐Arnáiz, I., & Yee, B. K. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.04.016 · Cited by 23 · see citing works
Pirbhoy, P. S., Jonak, C. R., Syed, R., Argueta, D. A., Perez, P. A., Wiley, M. B., Hessamian, K., Lovelace, J. W., Razak, K. A., DiPatrizio, N. V., et al. (2021) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09394-x · Cited by 23 · see citing works
Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study
Ma, L. X., Platnick, S., & Platnick, H. (2022) · Cureus · doi:10.7759/cureus.28442 · Cited by 23 · see citing works
Crespi, B. J. (2019) · Evolution Medicine and Public Health · doi:10.1093/emph/eoz022 · Cited by 23 · see citing works
Medicinal cannabis in children and adolescents with autism spectrum disorder: A scoping review
Fletcher, S., Pawliuk, C., Ip, A., Huh, L. L., Rassekh, S. R., Oberlander, T. F., & Siden, H. B. (2021) · Child Care Health and Development · doi:10.1111/cch.12909 · Cited by 22 · see citing works
Autism and associated disorders: cannabis as a potential therapy
Babayeva, M., Assefa, H., Basu, P., & Loewy, Z. G. (2022) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1401001 · Cited by 21 · see citing works
Staben, J., Koch, M., Reid, K., Muckerheide, J., Gilman, L., McGuinness, F., Kiesser, S., Oswald, I. W. H., Koby, K. A., Martin, T. J., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1185737 · Cited by 23 · see citing works
Montagner, P. S. S., Medeiros, W., da Silva, L. C. R., Borges, C. N., Brasil-Neto, J. P., Barbosa, V. D. D. S., Caixeta, F. V., & Malcher‐Lopes, R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1210155 · Cited by 20 · see citing works
Differential Adulthood Onset mGlu5Signaling Saves Prefrontal Function in the Fragile X Mouse
Martin, H. G. S., Lassalle, O., & Manzoni, O. J. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw328 · Cited by 20 · see citing works
Dallabrida, K. G., Bender, J. M. D. O., Chade, E. S., Rodrigues, N., & Sampaio, T. B. (2024) · Brain Sciences · doi:10.3390/brainsci14060592 · Cited by 20 · see citing works
Fyke, W., Alarcón, J. M., Velinov, M. T., & Chadman, K. K. (2021) · Autism Research · doi:10.1002/aur.2520 · Cited by 19 · see citing works
Pandina, G., Ring, R. H., Bangerter, A., & Ness, S. L. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.08.003 · Cited by 18 · see citing works
Denucci, B. L., de Lima, L. S., Mota, I. F. L., Azevedo, J. R. M., Veras, L. G., Bicca, J. V. M. L., Santana, B. D. M., Pinheiro, G. B., Coelho, G. G., & Mortari, M. R. (2021) · Reproductive Toxicology · doi:10.1016/j.reprotox.2021.10.010 · Cited by 17 · see citing works
A Spectrum of Solutions: Unveiling Non-Pharmacological Approaches to Manage Autism Spectrum Disorder
Mondal, A., Sharma, R., Abiha, U., Ahmad, F., Karan, A., Jayaraj, R. L., & Sundar, V. (2023) · Medicina · doi:10.3390/medicina59091584 · Cited by 17 · see citing works
Klein, M. E., Bangerter, A., Halter, R. J., Cooper, K. L., Aguilar, Z., Canuso, C. M., Drevets, W. C., Schmidt, M. E., & Pandina, G. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-02001-2 · Cited by 17 · see citing works
Schultz, S. T., Gould, G. G., Antonucci, N., Brigida, A. L., & Siniscalco, D. (2021) · Molecules · doi:10.3390/molecules26071845 · Cited by 17 · see citing works
SANTOS, R. G. D., Osório, F. D. L., Martín‐Santos, R., Zuardi, A. W., Hallak, J. E. C., & Crippa, J. A. S. (2019) · CNS Drugs · doi:10.1007/s40263-019-00669-5 · Cited by 17 · see citing works
Ahmed, M., Best, L. M., Pereira, C. F., Boileau, I., & Kloiber, S. M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104680 · Cited by 14 · see citing works
A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment
Licitra, R., Marchese, M., Naef, V., Ogi, A., Martinelli, M., Kiferle, C., Fronte, B., & Santorelli, F. M. (2022) · Biomedicines · doi:10.3390/biomedicines10081820 · Cited by 15 · see citing works
Pandina, G., Ring, R. H., Bangerter, A., & Ness, S. L. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2019.12.004 · Cited by 16 · see citing works
Potential of cannabinoids as treatments for autism spectrum disorders
Nezgovorova, V., Ferretti, C. J., Taylor, B. P., Shanahan, E. C., Uzunova, G., Hong, K., Devinsky, O., & Hollander, E. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.048 · Cited by 15 · see citing works
Endocannabinoid markers in autism spectrum disorder: A scoping review of human studies
Pol, M. D., & Kolla, N. J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114256 · Cited by 14 · see citing works
Endocannabinoid System Unlocks the Puzzle of Autism Treatment via Microglia
Su, T., Yan, Y., Li, Q., Ye, J., & Pei, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.734837 · Cited by 14 · see citing works
Briones, B. A., Pitcher, M. N., Fleming, W., Libby, A., Diethorn, E. J., Haye, A. E., MacDowell, C. J., Zych, A. D., Waters, R. C., Buschman, T. J., et al. (2021) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.11.005 · Cited by 14 · see citing works
Disrupting the endocannabinoid system in early adolescence negatively impacts sociability
Cossio, D. M., Stadler, H., Michas, Z., Johnston, C. J., & López, H. H. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172832 · Cited by 13 · see citing works
Matthiesen, M., Khlaifia, A., Steininger, C. F. D., Dadabhoy, M., Mumtaz, U., & Arruda-Carvalho, M. (2023) · Molecular Brain · doi:10.1186/s13041-023-01028-8 · Cited by 13 · see citing works
Oxytocin excites dorsal raphe serotonin neurons and bidirectionally gates their glutamate synapses
Oubraim, S., Shen, R., & Haj‐Dahmane, S. (2023) · iScience · doi:10.1016/j.isci.2023.106707 · Cited by 12 · see citing works
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R. J., & Restrepo, B. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.24022006 · Cited by 15 · see citing works
Coccurello, R., Marrone, M. C., & Maccarrone, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869606 · Cited by 12 · see citing works
Jana, A., Nath, A., Sen, P., Kundu, S., Alghamdi, B. S. A., Abujamel, T. S., Saboor, M., Chan, W., Alexiou, A. T., Papadakis, M., et al. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08781-6 · Cited by 11 · see citing works
Jawed, B., Esposito, J. E., Pulcini, R., Zakir, S. K., Botteghi, M., Gaudio, F., Savio, D., Martinotti, C., Martinotti, S., & Toniato, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212453 · Cited by 10 · see citing works
Campanale, A., Siniscalco, D., & Marzo, V. D. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01145-7 · Cited by 11 · see citing works
Friuli, M., Eramo, B., Sepe, C., Kiani, M., Casolini, P., & Zuena, A. R. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.114929 · Cited by 11 · see citing works
Therapeutic potential of CBD in Autism Spectrum Disorder
Pedrazzi, J. F. C., Hassib, L., Ferreira, F. R., Hallak, J. E. C., Del-Bel, E., & Crippa, J. A. S. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.05.002 · Cited by 11 · see citing works
Sabatini, G., Boccadoro, I., Prete, R., Battista, N., & Corsetti, A. (2025) · Nutrients · doi:10.3390/nu17152470 · Cited by 8 · see citing works
Parrella, N.-F., Hill, A. T., Enticott, P. G., Botha, T., Catchlove, S. J., Downey, L. A., & Ford, T. C. (2025) · Autism Research · doi:10.1002/aur.70159 · Cited by 9 · see citing works
Rava, A., Buzzelli, V., Feo, A., Ascone, F., Trapano, M. D., Schiavi, S., Carbone, E., Pasquadibisceglie, A., Polticelli, F., Manduca, A., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111234 · Cited by 8 · see citing works
Cherry, A. L., Wheeler, M. J., Mathisova, K., & Miceli, M. D. (2024) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2024.1294939 · Cited by 7 · see citing works
Augmentation of Endogenous 2-Arachidonoylglycerol Mitigates Autistic Behaviors of BTBR Mice
Zou, M., Zhang, Y., Du, C., Yang, B., Guo, P., Liang, H., Zhang, Y., Tian, W., Yang, L., Liu, D., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04606-6 · Cited by 6 · see citing works
Premoli, M., Carone, M., Mastinu, A., Maccarinelli, G., Aria, F., Sweeney, E. M., Memo, M., & Bonini, S. A. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2024.0062 · Cited by 6 · see citing works
Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism
da Costa, M. D. A., Fernandes, G. Z., Maiochi, E., Ebs, M. F. P., Darós, F. D. S., Bolan, S. J., Costa, R. R. N., de Rezende, V. L., da Silva, G. C., de Bitencourt, R. M., et al. (2024) · Developmental Neurobiology · doi:10.1002/dneu.22955 · Cited by 8 · see citing works
Daily oscillation of the excitation/inhibition ratio is disrupted in two mouse models of autism
Bridi, M., Luo, N., Kim, G., Menarchek, B. J., Lee, R. A., Rodríguez, B. A., Severín, D., Moreno, C., Contreras, A., Wesselborg, C., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111494 · Cited by 5 · see citing works
Fletcher, S., Pawliuk, C., Ip, A., Oberlander, T. F., & Siden, H. B. (2020) · JBI Evidence Synthesis · doi:10.11124/jbies-20-00001 · Cited by 6 · see citing works
Combinatorial approaches for treating neuropsychiatric social impairment
Don, W., Tsheringla, S., McPartland, J. C., & Allsop, S. A. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0051 · Cited by 5 · see citing works
Behavioral and transcriptomic effects of a novel cannabinoid on a rat valproic acid model of autism
Loomis, S., Silva, D. G., Savopoulos, R., Cilia, J., Li, J. S. Y., Davis, M. D., Virley, D. J., Foley, A., Loro, E., & McCreary, A. C. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110450 · Cited by 4 · see citing works
Jia, X., Gao, S., Liu, X., Feng, Z., Wang, X. X., Lan, K., Lu, Y., Han, L., Wei, Y. B., & Liu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02031-x · Cited by 4 · see citing works
Safety and Efficacy of Cannabis in Autism Spectrum Disorder
Ganesh, A., & Shareef, S. (2020) · Pediatric Neurology Briefs · doi:10.15844/pedneurbriefs-34-25 · Cited by 4 · see citing works
Endocannabinoid contributions to the perception of socially relevant, affective touch in humans
Jones, M. R., Haggarty, C. J., Petrie, G. N., Lunge, A. R., Morrison, I., Hill, M. N., Heilig, M. A., & Mayo, L. M. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02053-y · Cited by 3 · see citing works
Potentiation of endocannabinoid signaling alleviates depressive-like behavior in diabetic mice
Kesharwani, A., Lahamge, D., Singh, S. K., Ravichandiran, V., & Parihar, V. K. (2025) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2025.100037 · Cited by 3 · see citing works
Wang, F., Gao, Y., Liu, Z., Cheng, Z., Liu, S., Zhang, Y., Jiang, W., Zhang, M., Yang, X., Zou, M., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110501 · Cited by 3 · see citing works
O’Brien, K., & Blair, P. (2021) · Springer eBooks · doi:10.1007/978-3-030-78559-8_10 · Cited by 3 · see citing works
Wang, H., Zhang, M., Yang, S., Jiang, Y. H., Wu, L., & Sun, C. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70591 · Cited by 2 · see citing works
Carbonell, A. U., Freire‐Cobo, C., Deyneko, I. V., Erdjument‐Bromage, H., Clipperton‐Allen, A. E., Rasmusson, R. L., Page, D. T., Neubert, T. A., & Jordan, B. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.02.429412 · Cited by 2 · see citing works
Cannabis Compounds: Potential Therapy for Neurological Disease
Babayeva, M., & Loewy, Z. G. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005770 · Cited by 1 · see citing works
Endocannabinoid System Contributions to Psychiatric Risk
Lunge, A. R., Tansey, R. C., Elliott, G., Ferger, M. D., & Mayo, L. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-87990-6_15 · Cited by 1 · see citing works
Endocannabinoids and social behavior
Trezza, V., Rava, A., & Feo, A. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00019-0 · Cited by 1 · see citing works
- Authors
- Wei, D., Dinh, D., Lee, D., Li, D., Anguren, A., Moreno-Sanz, G., Gall, C. M., & Piomelli, D.
- Affiliations
- Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, California.
- University of California, Irvine (US)
- Harbin Medical University (CN)
- Corresponding author
- Piomelli, Daniele
- Venue
- Cannabis and Cannabinoid Research
- Publisher
- SAGE Publications
- Published
- 2016-12
- Volume
- 1
- Issue
- 1
- Pages
- 81-89
- ISSN
- 2378-8763 (ISSN-L)
- PMC
- PMC5549436
- OpenAlex
- W2293191501
- Cited by
- 122
- References
- 51
- Citations by year
- 2026: 4 · 2025: 17 · 2024: 15 · 2023: 14 · 2022: 11 · 2021: 25 · 2020: 11 · 2019: 14 · 2018: 3 · 2017: 4 · 2016: 4
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cannabis and Cannabinoid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Autism Science Foundation
- National Institutes of Health
- University of California, Irvine
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
- Keywords
- anandamide, endocannabinoid system, autism spectrum disorder, social dysfunction, oxytocin, social reward, fatty acid amide hydrolase, FAAH inhibition, URB597, CB1 receptor, BTBR mice, Fmr1 knockout mice, fragile X syndrome, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-09.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-09.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review